CO4750827A1 - Compuestos - Google Patents

Compuestos

Info

Publication number
CO4750827A1
CO4750827A1 CO96048962A CO96048962A CO4750827A1 CO 4750827 A1 CO4750827 A1 CO 4750827A1 CO 96048962 A CO96048962 A CO 96048962A CO 96048962 A CO96048962 A CO 96048962A CO 4750827 A1 CO4750827 A1 CO 4750827A1
Authority
CO
Colombia
Prior art keywords
alkyl
aryl
heterocyclyl
hydrogen
vivo
Prior art date
Application number
CO96048962A
Other languages
English (en)
Inventor
Martin Leonard Gilpin
David John Payne
John Hargreaves Bateson
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9518920.5A external-priority patent/GB9518920D0/en
Priority claimed from GBGB9610902.0A external-priority patent/GB9610902D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of CO4750827A1 publication Critical patent/CO4750827A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un método de tratamiento de infecciones bacterianas en sereshumanos o animales, que comprende administrar, en combinación con un antibiótico del tipo de ß-lactama, una cantidad eficaz terapéuticamente de un compuesto de fórmula (I) o una sal farmacéuticamente estable, solvato o éster hidrolizable in vivo del mismo: en la que:X es S, S(O)n o CH2 ; n es 1 ó 2; R es hidrógeno, un catión formador de sales o un grupo formador de ésteres hidrolizables in vivo; R1 y R2 son cada uno hidrógeno o un grupo sustituyente orgánico; R3 es hidrógeno, alquilo (C1-6 ) opcionalmente sustituido con hasta tres átomos de halógeno, alquenilo (C2-6 ), alquinilo (C2-6 ), arilo, aril-alquilo (C1-6 ) heterociclilo o heterociclil-alquilo (C1-6 ); y R4 es hidrógeno, o un grupo acilo hidrolizable in vivo. Un compuesto de formula (IA) o una sal farmacéuticamente aceptable, solvato o éster hidrolizable in vivo del mismo:en el que R3 1 representa alquilo (C1-6 ) sustituido con hasta tres átomos de halógeno, arilo, aril-alquilo (C1-6 ), heterociclilo o heterociclil-alquilo (C1-6 ) y X es S.
CO96048962A 1995-09-15 1996-09-13 Compuestos CO4750827A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9518920.5A GB9518920D0 (en) 1995-09-15 1995-09-15 Chemical compounds
GBGB9610902.0A GB9610902D0 (en) 1996-05-24 1996-05-24 Compounds

Publications (1)

Publication Number Publication Date
CO4750827A1 true CO4750827A1 (es) 1999-03-31

Family

ID=26307769

Family Applications (1)

Application Number Title Priority Date Filing Date
CO96048962A CO4750827A1 (es) 1995-09-15 1996-09-13 Compuestos

Country Status (6)

Country Link
US (1) US6022885A (es)
EP (1) EP0850230A1 (es)
AU (1) AU7084996A (es)
CA (1) CA2230122A1 (es)
CO (1) CO4750827A1 (es)
WO (1) WO1997010225A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704522D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Compounds
WO1998040056A2 (en) * 1997-03-13 1998-09-17 Smithkline Beecham Plc Pyrrolidine and thiazole derivatives with metallo-beta-lactamase inhibitory properties
US6218550B1 (en) * 1997-05-23 2001-04-17 Eisai Co., Ltd. Intermediates useful for the manufacture of carbapenem and a stereoselective manufacturing method therefor
PT915088E (pt) 1997-10-31 2003-01-31 Hoffmann La Roche Derivados de d-prolina
JP2002543129A (ja) * 1999-05-05 2002-12-17 メルク エンド カムパニー インコーポレーテッド 抗微生物剤としての新規なプロリン類
US6630510B1 (en) 1999-10-28 2003-10-07 Merck & Co., Inc. Substituted succinic acid metallo-β-lactamase inhibitors and their use in treating bacterial infections
RU2462450C2 (ru) 2005-09-22 2012-09-27 Мейдзи Сейка Кайся, Лтд. ИНГИБИТОРЫ МЕТАЛЛО-β-ЛАКТАМАЗЫ
US20120329842A1 (en) * 2010-12-23 2012-12-27 Yongcheng Song Small molecule compounds as broad-spectrum inhibitors of metallo-beta-lactamases
GB201317619D0 (en) 2013-10-04 2013-11-20 Uni I Oslo Compounds
GB201613946D0 (en) 2016-08-15 2016-09-28 Univ Oslo Compounds
CN108084075A (zh) * 2016-11-21 2018-05-29 天津大学 具有β-内酰胺酶抑制作用的脯氨酸衍生物
CN108078982B (zh) * 2016-11-21 2020-02-07 天津大学 脯氨酸衍生物在制备β-内酰胺酶抑制剂中的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105776A (en) * 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4046889A (en) * 1976-02-13 1977-09-06 E. R. Squibb & Sons, Inc. Azetidine-2-carboxylic acid derivatives
JPS5834474B2 (ja) * 1977-06-29 1983-07-27 ウェルファイド株式会社 チアゾリジン誘導体の製造法
CH635087A5 (en) * 1977-09-23 1983-03-15 Squibb & Sons Inc Substituted thiazolidine-, thiazane- and oxazane-carboxylic acids and carboxylic acid esters.
US4283407A (en) * 1977-09-28 1981-08-11 Science Union Et Cie Thiopropionamides, and the pharmaceutical compositions
JPS5455565A (en) * 1977-10-06 1979-05-02 Santen Pharmaceut Co Ltd Novel thiazolidine derivative
JPS559060A (en) * 1978-07-07 1980-01-22 Yoshitomi Pharmaceut Ind Ltd Thia(oxa)zolidinecarboxylic acid derivative and its prepatation
US4316906A (en) * 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
US4307110A (en) * 1980-09-12 1981-12-22 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of 3-substituted proline derivatives
JPH06740B2 (ja) * 1984-08-16 1994-01-05 三菱レイヨン株式会社 光学活性カルボン酸アミドの製造法
JPH0557561A (ja) * 1991-09-03 1993-03-09 Shokuhin Kikai Kiban Gijutsu Kaihatsu Kk 食品切裁作業消費エネルギを節減する制御方法および同制御装置

Also Published As

Publication number Publication date
AU7084996A (en) 1997-04-01
WO1997010225A1 (en) 1997-03-20
US6022885A (en) 2000-02-08
EP0850230A1 (en) 1998-07-01
CA2230122A1 (en) 1997-03-20

Similar Documents

Publication Publication Date Title
CO4750827A1 (es) Compuestos
AR009357A1 (es) Compuesto de amidas de acido fosfinico y sus usos para preparar una composicion farmaceutica y en un metodo para prevenir o tratar unaenfermedad asociada a la actividad de metaloproteasa
ES2080900T3 (es) Derivados piranicos utiles como inhibidores de 5-lipoxigenasa.
ATE4903T1 (de) 1-, 6- und 2-substituierte 1-carba-2-penem-3carbons[ure, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
BR0113039A (pt) Composto ou um seu sal ou solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica em aerossol, método para o tratamento de um indivìduo humano ou animal com uma condição antiinflamatória e/ou alérgica, e, processo para preparar um composto
BG93979A (bg) Производни на n-(4-пиперидинил)(дихидробензофуран или дихидро-2н-бензопиран)карбоксамид, фармацевтичен състав, който ги съдържа, метод за получаване на производните и приложението им
UY26161A1 (es) Derivados de 13-metil eritromicina
FR2619111B1 (fr) Derives de (piperidinyl-4)methyl-2 tetrahydro-1,2,3,4 9h-pyrido (3,4-b) indole, leur preparation et leur application en therapeutique
AR039385A1 (es) Derivados de tioxantina como inhibidores de la mieloperoxidasa
PE32296A1 (es) Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables
AR026974A1 (es) N-[5-[[[5-alquil-2-oxazolil]metil]tio]-2-tiazolil]-carboxamidas, utiles como inhibidores de cinasas dependientes de ciclina, y las composicionesfarmaceuticas que los contienen
GT199700037A (es) Composiciones farmaceuticas para el tratamiento de la rinitis
ES2148305T3 (es) Derivados de aminoacidos ciclicos que tienen actividad inhibidora de ace y nep.
NO942309L (no) 5-amino-8-methyl-7-pyrrolidinylkinolin-3-carboxylsyrederivater
NO160297C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-oksoazetidinderivater
GB2006195A (en) 2-Azetidinone Derivatives
CO4960654A1 (es) Metodo para el tratamiento de enfermedades fisiologicas relacionadas con el uso o con las secuelas provocadas por el uso de la cocaina u otros estimulantes psicomotores
AR039475A1 (es) 6-alquiliden-penems triciclicos como inhibidores de beta-lactamasa
ES2109988T3 (es) Derivados cefalosporinicos.
SE8500965D0 (sv) Mellanprodukter for framstellning av beta-laktamasinhibitorer
EA200001029A1 (ru) Производные гигромицина
AR007052A1 (es) Un derivado de carbohidrato, su uso y una composicion farmaceutica que lo comprende
AR009987A1 (es) Derivados de beta-tiopropionilaminoacidos, composiciones farmaceuticas que incluyen dichos derivados, procedimiento para prepararlos, uso de dichosderivados para el tratamiento de infecciones bacterianas y compuestos intermediarios de aplicacion en dicho procedimiento
HUP0003475A2 (hu) Neutrofil-elasztáz gátló hatású pirrolo-pirrolon-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
SE8603309D0 (sv) Mellanprodukter for framstellning av penicillansyra-1,1-dioxid och estrar derav